analyst
PT
NASDAQ · PTCT
PTC Therapeutics, Inc.
Healthcare · Biotechnology
$65.65
Down-$0.83 (-1.25%)
Updated Sep 16, 2026, 8:45 AM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.05B
- P/E ratio
- 7.87
- Dividend yield
- 0.00%
- 52-week range
- $57.74 – $90.87
- Volume
- 1.03M
- Avg. volume
- 1.55M
Price performance
PTCT price history
1M range · 20 trading sessions · Daily adjusted prices
PTCT closed at $65.65 after 20 trading sessions, down 9.61% for the selected period.
- Last close
- $65.65
- Period change
- -9.61%
- Period low
- $65.65
- Period high
- $73.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $66.51 | $66.54 | $65.06 | $65.65 | 1.03M |
| Sep 14, 2026 | $67.09 | $67.99 | $65.91 | $66.48 | 1.02M |
| Sep 11, 2026 | $67.80 | $68.48 | $65.91 | $66.06 | 792.89K |
| Sep 10, 2026 | $66.84 | $67.78 | $66.47 | $67.37 | 1.01M |
| Sep 9, 2026 | $68.08 | $68.84 | $67.50 | $67.57 | 1.07M |
| Sep 8, 2026 | $67.81 | $70.08 | $67.475 | $68.81 | 1.12M |
| Sep 4, 2026 | $70.62 | $71.405 | $69.26 | $69.30 | 673.54K |
| Sep 3, 2026 | $71.76 | $71.97 | $70.55 | $71.40 | 654.52K |
| Sep 2, 2026 | $71.15 | $72.68 | $69.835 | $71.79 | 902.58K |
| Sep 1, 2026 | $69.42 | $70.84 | $69.05 | $70.56 | 691.02K |
| Aug 31, 2026 | $69.98 | $70.42 | $68.755 | $69.54 | 841.1K |
| Aug 28, 2026 | $71.08 | $71.49 | $69.61 | $70.09 | 692.68K |
| Aug 27, 2026 | $72.11 | $72.66 | $70.91 | $71.81 | 746.33K |
| Aug 26, 2026 | $73.18 | $73.525 | $71.81 | $72.69 | 533.67K |
| Aug 25, 2026 | $71.69 | $73.47 | $71.69 | $73.47 | 624.46K |
| Aug 24, 2026 | $69.67 | $71.45 | $68.02 | $71.06 | 897.68K |
| Aug 21, 2026 | $70.54 | $71.36 | $69.79 | $69.82 | 674.74K |
| Aug 20, 2026 | $73.05 | $73.56 | $70.46 | $70.52 | 802.51K |
| Aug 19, 2026 | $73.72 | $74.02 | $72.215 | $73.67 | 1.51M |
| Aug 18, 2026 | $72.86 | $74.03 | $72.225 | $72.63 | 731.63K |
Latest PTCT news
The latest Smart Investors Daily articles mentioning PTCT.
Stock researchCompany · Overview
PTCT research
Overview
Company profile and research snapshot.
Company profile
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $74.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Barclays | Overweight | — |
| Aug 13, 2026 | Wells Fargo | Overweight | — |
| Jul 31, 2026 | Morgan Stanley | Overweight | — |
| Jul 31, 2026 | Wells Fargo | Overweight | — |
| Jul 20, 2026 | Wells Fargo | Overweight | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.